Associate Professor, Department of Pathology Tumor Cell Biology ProgramMD, Biophysics, Second Moscow State Medical Institute, Moscow, USSR, 1981PhD, Immunology, Institute of Tuberculosis, Moscow, USSR, 1989Postdoc, 1991-94, University of Virginia, Charlottesville, VAPostdoc, 1994-98, Northwestern University, Chicago, IL
Contact information2500 N State St., Suite G758Jackson, MS 39216Phone: (601) 815-6072E-mail: email@example.com
The studies on bone metastases include identification of genes that are involved in the interaction of cancer cells with the bone using gene array technology and further determination of their functional roles in bone metastases by applying siRNA technology and intracardiac models in vivo. Identification of "bone metastastatic signature" allowed us to focus on selected candidate genes that hold promise as potential biomarkers and therapeutic targets of bone metastases. We have shown that one of these genes, metastasis-associated protein 1 (MTA1) plays a critical role in prostate cancer progression by inhibiting apoptosis and promoting angiogenesis. We also have evidence that MTA1 can serve as an independent prognostic marker for aggressive prostate cancer.
Another major interest is potential chemopreventive and therapeutic efficacy of dietary agents such as resveratrol and its potent analogues in prostate cancer. We found that resveratrol/analogues inhibit MTA1 and rescue acetylation of tumor suppressors p53 and PTEN. The novel MTA1-mediated epigenetic mechanism of action of dietary compounds is under intensive investigation in my laboratory.
We are also interested in another epigenetic regulatory network which is represented by microRNAs and Epi-microRNAs.
2500 North State Street
Jackson, MS 39216
General Information: 601-984-1000
Patient Appointments: 888-815-2005